Keywords: cv, thera, ranexa, fails, acs, study, californian

CV Thera's Ranexa fails in ACS study

Article | 19 March 2007

Print This

Californian drugmaker CV Therapeutics says that its heart drug Ranexa (ranolazine) has failed to achieve the primary efficacy endpoint in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in